{"doi":"10.3945/an.114.007732","title":"Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs","abstract":null,"journal":"Advances in Nutrition","year":2015,"id":144958,"datarank":9.522060142274894,"base_score":6.690842277418564,"endowment":6.690842277418564,"self_citation_contribution":1.0036263416127846,"citation_network_contribution":8.518433800662109,"self_endowment_contribution":1.0036263416127846,"citer_contribution":8.518433800662109,"corpus_percentile":null,"corpus_rank":null,"citation_count":804,"citer_count":200,"citers_with_citation_signal":200,"citers_with_endowment":200,"datacite_reuse_total":25,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":614107,"name":"Shan Leng","orcid":"0000-0003-3933-7551","position":1,"is_corresponding":false},{"id":614108,"name":"Jessay G Devassy","orcid":"0000-0003-4004-7359","position":2,"is_corresponding":false},{"id":614109,"name":"Md Monirujjaman","orcid":"0000-0003-2773-3530","position":3,"is_corresponding":false},{"id":614110,"name":"Harold M Aukema","orcid":"0000-0002-6982-7239","position":4,"is_corresponding":false},{"id":614106,"name":"Melissa Gabbs","orcid":"0000-0001-7784-4779","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs","abstract":"Oxylipins formed from polyunsaturated fatty acids (PUFAs) are the main mediators of PUFA effects in the body. They are formed via cyclooxygenase, lipoxygenase, and cytochrome P450 pathways, resulting in the formation of prostaglandins, thromboxanes, mono-, di-, and tri-hydroxy fatty acids (FAs), epoxy FAs, lipoxins, eoxins, hepoxilins, resolvins, protectins (also called neuroprotectins in the brain), and maresins. In addition to the well-known eicosanoids derived from arachidonic acid, recent developments in lipidomic methodologies have raised awareness of and interest in the large number of oxylipins formed from other PUFAs, including those from the essential FAs and the longer-chain n-3 (ω-3) PUFAs. Oxylipins have essential roles in normal physiology and function, but can also have detrimental effects. Compared with the oxylipins derived from n-3 PUFAs, oxylipins from n-6 PUFAs generally have greater activity and more inflammatory, vasoconstrictory, and proliferative effects, although there are notable exceptions. Because PUFA composition does not necessarily reflect oxylipin composition, comprehensive analysis of the oxylipin profile is necessary to understand the overall physiologic effects of PUFAs mediated through their oxylipins. These analyses should include oxylipins derived from linoleic and α-linolenic acids, because these largely unexplored bioactive oxylipins constitute more than one-half of oxylipins present in tissues. Because collated information on oxylipins formed from different PUFAs is currently unavailable, this review provides a detailed compilation of the main oxylipins formed from PUFAs and describes their functions. Much remains to be elucidated in this emerging field, including the discovery of more oxylipins, and the understanding of the differing biological potencies, kinetics, and isomer-specific activities of these novel PUFA metabolites.","is_dataset_classified":null,"base_score":6.690842277418564,"endowment":6.690842277418564,"datacite_reuse_total":25,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"26374175","pmcid":"PMC4561827","openalex_id":"https://openalex.org/W2101841000","authors":[],"funders":[],"total_grants":0,"fwci":17.0294,"citation_percentile":0.99644444,"influential_citations":60,"citation_trend":[{"year":2015,"count":1},{"year":2016,"count":14},{"year":2017,"count":31},{"year":2018,"count":42},{"year":2019,"count":62},{"year":2020,"count":85},{"year":2021,"count":106},{"year":2022,"count":110},{"year":2023,"count":107},{"year":2024,"count":96},{"year":2025,"count":92},{"year":2026,"count":58}],"oa_status":"bronze","license":"http://creativecommons.org/licenses/by-nc-nd/4.0/","oa_locations":[{"url":"https://academic.oup.com/advances/article-pdf/6/5/513/23738985/an007732.pdf","host_type":"journal"},{"url":"https://academic.oup.com/advances/article-pdf/6/5/513/23738985/an007732.pdf","host_type":"HYBRID"},{"url":"https://academic.oup.com/advances/article-pdf/6/5/513/23738985/an007732.pdf","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S2161831323000984?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S2161831323000984?httpAccept=text/plain","host_type":"publisher"},{"url":"http://academic.oup.com/advances/article-pdf/6/5/513/23738985/an007732.pdf","host_type":"publisher"},{"url":"https://doi.org/10.3945/an.114.007732","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/26374175","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4561827","host_type":"repository"}],"fields_of_study":["Eicosanoids and Hypertension Pharmacology","Fatty Acid Research and Health","Alcohol Consumption and Health Effects","Medicine","Biology","Chemistry","Cytochrome P-450 Enzyme System","Fatty Acids, Omega-3","Fatty Acids, Omega-6","Humans","Lipoxygenase","Oxylipins","Prostaglandin-Endoperoxide Synthases"],"mesh_terms":["Cytochrome P-450 Enzyme System","Humans","Lipoxygenase","Prostaglandin-Endoperoxide Synthases","Fatty Acids, Omega-3","Fatty Acids, Omega-6","Oxylipins"],"keywords":["Oxylipin","Polyunsaturated fatty acid","Thromboxanes","Lipoxygenase","Chemistry","Arachidonic acid","Isoprostanes","Biochemistry","Lipid signaling","Eicosanoid","Fatty acid","Enzyme","Cyclooxygenase","Cytochrome p450","Omega-3","Omega-6","Lipidomics","Lipid Mediators","Lipooxygenase"],"sdg_mappings":[],"linked_datasets":[{"doi":"10.6084/m9.figshare.15048953.v1","title":"Additional file 1 of Differences in oxylipin profile in psoriasis versus psoriatic arthritis","publisher":"figshare","resource_type":"Presentation"},{"doi":"10.6084/m9.figshare.15048953","title":"Additional file 1 of Differences in oxylipin profile in psoriasis versus psoriatic arthritis","publisher":"figshare","resource_type":"Presentation"},{"doi":"10.6084/m9.figshare.15063886.v1","title":"Additional file 1 of Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15063886","title":"Additional file 1 of Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15063895.v1","title":"Additional file 2 of Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15063895","title":"Additional file 2 of Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15063898.v1","title":"Additional file 3 of Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15063898","title":"Additional file 3 of Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15063901.v1","title":"Additional file 4 of Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15063901","title":"Additional file 4 of Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15063904.v1","title":"Additional file 5 of Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15063904","title":"Additional file 5 of Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15063913.v1","title":"Additional file 6 of Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15063913","title":"Additional file 6 of Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15063919.v1","title":"Additional file 7 of Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15063919","title":"Additional file 7 of Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15063928.v1","title":"Additional file 8 of Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.15063928","title":"Additional file 8 of Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16575423.v1","title":"Additional file 10 of Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer’s disease","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16575423","title":"Additional file 10 of Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer’s disease","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16575432.v1","title":"Additional file 11 of Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer’s disease","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16575432","title":"Additional file 11 of Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer’s disease","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16575435.v1","title":"Additional file 1 of Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer’s disease","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16575435","title":"Additional file 1 of Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer’s disease","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.16575438.v1","title":"Additional file 2 of Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer’s disease","publisher":"figshare","resource_type":"JournalArticle"}],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-18T23:40:17.412810Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}